Overview
- Emcure will commercialise and market Poviztra nationwide as Novo Nordisk India’s appointed exclusive distributor.
- Distribution efforts prioritise retail pharmacies and geographies not previously covered by Novo Nordisk India.
- Poviztra is a second brand of Wegovy (semaglutide 2.4 mg), indicated as an adjunct to diet and physical activity for chronic weight management and to reduce major cardiovascular risks.
- Companies cited STEP and SELECT programmes showing roughly one in three patients achieved over 20% weight loss, supported by extensive real-world use.
- Emcure shares climbed about 6–8% intraday after the announcement, outperforming the broader market.